BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by Roth Mkm

Posted by on May 28th, 2026

BioAge Labs (NASDAQ:BIOA – Get Free Report) was upgraded by stock analysts at Roth Mkm to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Several other brokerages have also issued reports on BIOA. Citigroup boosted their target price on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Needham & Company LLC started coverage on BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 target price for the company. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Piper Sandler started coverage on BioAge Labs in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. Finally, BTIG Research started coverage on BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioAge Labs currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

Read Our Latest Stock Analysis on BioAge Labs

BioAge Labs Trading Up 4.6%

Shares of BIOA stock opened at $16.95 on Wednesday. BioAge Labs has a 12-month low of $3.79 and a 12-month high of $24.00. The stock’s 50-day moving average price is $17.54 and its 200-day moving average price is $16.37. The stock has a market capitalization of $753.43 million, a price-to-earnings ratio of -7.06 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA – Get Free Report) last issued its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.The firm had revenue of $2.77 million for the quarter. As a group, research analysts predict that BioAge Labs will post -2.59 EPS for the current fiscal year.

Hedge Funds Weigh In On BioAge Labs

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its holdings in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after purchasing an additional 1,685,063 shares during the last quarter. Octagon Capital Advisors LP lifted its holdings in shares of BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of BioAge Labs by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of BioAge Labs during the 4th quarter valued at $13,892,000. Finally, Geode Capital Management LLC lifted its holdings in shares of BioAge Labs by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock valued at $7,826,000 after purchasing an additional 28,646 shares during the last quarter.

About BioAge Labs

(Get Free Report)

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

Featured Stories

Analyst Recommendations for BioAge Labs (NASDAQ:BIOA)

Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.